Biocon Biologics Ltd., a fully integrated 'pure play' biosimilars company and a subsidiary of Biocon Ltd. has signed an agreement with the Clinton Health Access Initiative (CHAI) to expand access to lifesaving cancer biosimilars in over 30 countries in Africa and Asia as a part of the Cancer Access Partnership (CAP).

The partnership is a significant step in delivering advanced cancer therapies to patients who need them the most and ensuring equitable access to high-quality biosimilars in low- and middle-income countries (LMICs).

Kiran Mazumdar-Shaw, Executive Chairperson, Biocon Biologics said: "Biocon Biologics has been in the forefront of a long-running crusade against cancer through its high quality affordable biosimilars. The collaboration with CHAI further strengthens our resolve to address the unmet patient needs in Asia and Africa for advanced cancer therapies through costeffective alternatives to expensive reference biologics. This is an extension of our commitment to enable universal access to cancer patients following the initiation of our Mission 10 cents to provide insulins for people with diabetes in LMICs."

Dr. Christiane Hamacher, CEO, Biocon Biologicssaid: "We are extremely proud to collaborate with CHAI to realise our mission of enabling universal access to quality cancer care. Biocon Biologics is reimagining access to biologicsin LMICs through strategic partnerships with global health organisations. We are committed to reducing the high cost of cancer care for healthcare systems through our biosimilars and are pleased to address the needs of patients in Africa and Asia through the Cancer Access Partnership (CAP)."

CHAI CEO, Dr. Ian Barton stated: "Expanding the Cancer Access Partnership to include highquality biologics from Biocon takes us another step closer to ensuring that cancer patients have access to the quality medications that they need at an affordable price, no matter where they live. We welcome the new commitments and we look forward to partnering to bring these high-quality medicines to patients."

As a committed global player in Biosimilars, Biocon Biologics is leveraging its science, scale and expertise to shift the access paradigm for patients in need of biosimilars across the globe. Biocon Biologics has developed monoclonal antibodies and therapeutic proteins for oncology, which are having a significant impact in the area of cancer care in several developed and emerging markets by providing high-quality, cost-effective alternatives to expensive reference biologics.